Rallybio’s lead program has crashed out. Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare maternal immune disorder in response to phase 2 data. $RLYB fiercebiotech.com/biotech/rallyb…

A US congressional commission has made the case for “swift action” to maintain the nation’s role as a biotech superpower, while warning the sector is “dangerously close to falling behind China.” fiercebiotech.com/biotech/congre…

With two attempts to merge with other companies having collapsed, Vincerx Pharma has been left with no choice but to start winding down. $VINC fiercebiotech.com/biotech/vincer…

Valiltramiprosate was no better than placebo at slowing cognitive decline in the phase 3 trial, causing the study—which included 325 people with early Alzheimer’s—to miss its primary endpoint. fiercebiotech.com/biotech/alzheo…

“No one was saying 2025 was going to be an awesome year for biotech IPOs, in particular,” Adam Farlow, Global Chair of Baker McKenzie’s Capital Markets Practice Group, told James Waldron. “Last week's announcements created additional volatility. Equity markets hate volatility,

Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticaria drug into phase 2, instead preparing to sell the asset while liquidating the business. fiercebiotech.com/biotech/third-…

Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX40-ligand monoclonal antibody missed the main goal of a phase 2 asthma study. $SNY fiercebiotech.com/biotech/sanofi…

Essa Pharma is facing a call to wind down operations. One of the biotech’s largest shareholders put the proposal to Essa’s board after concluding that the best option is to return cash to investors. $EPIX fiercebiotech.com/biotech/invest…

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. $LLY fiercebiotech.com/biotech/lillys…

Nine months after Johnson & Johnson stepped back from an Addex Therapeutics-partnered epilepsy drug in the wake of a phase 2 fail, the Big Pharma has now fully severed its relationship with the Swiss biotech. #ADXN $JNJ fiercebiotech.com/biotech/jj-cal…

VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up to $440 million. fiercebiotech.com/biotech/stealt…

The US government has terminated a $4.2M contract for Pluri Biotech’s PLX-R18 cell therapy in a move that the biotech believes “may reflect broader federal budgetary and administrative adjustments." fiercebiotech.com/biotech/nih-ni…

New #NIH grant rules override the Civil Rights Act of 1964, barring recipients from DEI activities fiercebiotech.com/research/new-n… by FierceBiotech #Alzheimers #dementia #science

Sanofi’s development of an oral spin on Humira’s mechanism has fallen short in a ph. 2 psoriasis trial, prompting the French drugmaker to pull back from plans to develop the molecule as a monotherapy. $SNY fiercebiotech.com/biotech/sanofi…

A study of almost 34,000 people in rural China has revealed that lowering blood pressure can reduce the risk of dementia in patients with hypertension. fiercebiotech.com/research/massi…

Spruce Biosciences has swept away 55% of its employees. The biotech took the action days after inking a deal for a former BioMarin rare disease candidate that it plans to file for a speedy approval next year. fiercebiotech.com/biotech/spruce…

The HHS has lifted a stop work order on Vaxart’s phase 2b trial testing out a COVID-19 vaccine pill, with the biotech resuming plans to enroll participants for the 10,000-person study. $VXRT fiercebiotech.com/biotech/hhs-li…

Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program and running into unresolved biology questions. fiercebiotech.com/biotech/octago…

Pink slips have followed the green light at Entrada Therapeutics. Weeks after the FDA lifted a more than two-year-long hold, the biotech has set out plans to reduce its workforce by 20%. $TRDA fiercebiotech.com/biotech/entrad…

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor degrader R&D plan in the wake of mixed data. Arvinas is also is laying off a third of its staff to cut costs and extend its cash runway. $PFE $ARVN fiercebiotech.com/biotech/arvina…